Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: Report of a prospective (Phase II) multicenter study

Journal of Vascular Surgery

Volumn 36, Issue 1, 2002, Pages 1-12

  Baxter, B Timothy ^a   Pearce, William H ^c   Waltke, Eugene A ^b   Littooy, Fred N ^d   Hallett Jr , John W ^e   Kent, K Craig ^f   Upchurch Jr , Gilbert R ^g   Chaikof, Elliot L ^h   Mills, Joseph L ⁱ   Fleckten, Beverly ^a   Longo, G Matt ^a   Lee, Jason K ^j   Thompson, Robert W ^j  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c NORTHWESTERN UNIVERSITY MEDICAL CENTER   (United States)

^d LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

^f Department of Obstetrics Gynecology   (United States)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF ARIZONA   (United States)

^j WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; GELATINASE B; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER;

ABDOMINAL AORTA ANEURYSM; ABDOMINAL CRAMP; ADULT; AGED; ARTICLE; BLOATING; CANDIDIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; MALE; MULTICENTER STUDY; MYCOSIS; NAUSEA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHOTOSENSITIVITY DISORDER; PLANTAR FASCIITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; TOOTH COLOR; BLOOD; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG EFFECT; FOLLOW UP; MIDDLE AGED; STATISTICS; TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AORTIC ANEURYSM, ABDOMINAL; BIOLOGICAL MARKERS; DISEASE PROGRESSION; DOXYCYCLINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; STATISTICS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0036634195     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1067/mva.2002.125018     Document Type: Article

References (46)

1. Keen RR, Dobrin PB. Development of aneurysms. Georgetown, Tex: Landes Bioscience; 2000.
2. The UK Small Aneurysm Trial Participants. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. Lancet 1998;352:1649-55.
3. Lederle FA, Wilson SE, Johnson GRJ, Reinke DB, Littooy FN, Acher CW, et al. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Investigators. A comparison of immediate repair and imaging surveillance of small abdominal aortic aneurysms. N Engl J Med. In press 2002.
4. Alcorn HG, Wolfson SK Jr, Sutton-Tyrrell IC, Kuller LH, O'Leary D. Risk factors for abdominal aortic aneurysms in older adults enrolled in The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1996; 16:963-70.
5. Brown PM, Pattenden R, Vernooy C, Zelt DT, Gutelius JR. Selective management of abdominal aortic aneurysms in a prospective measurement program. J Vasc Surg 1996;23:213-20.
6. Cronenwett JL, Sargent SK, Wall MH, Hawkes ML, Freeman DH, Dain BJ, et al. Variables that affect the expansion rate and outcome of small abdominal aortic aneurysms. J Vasc Surg 1990;11:260-9.
7. Brown LC, Powell JT, UK Small Aneurysm Trial Participants. Risk factors for aneurysm rupture in patients kept under ultrasound surveillance. Ann Surg 1999;230:289-96.
8. Thompson RW. Basic science of abdominal aortic aneurysms: emerging therapeutic strategies for an unresolved clinical problem. Curr Opin Cardiol 1996;11:504-18.
9. Thompson RW, Parks WC. Role of matrix metalloproteinases in abdominal aortic aneurysms. Ann N Y Acad Sci 1996;800:157-74.
10. Thompson RW, Holmes DR, Mertens RA, Liao S, Botney MD, Mecham RP, et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms: an elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest 1995;96:318-26.
11. McMillan WD, Patterson BK, Keen RR, Shively VP, Cipollone M, Pearce WH. In situ localization and quantification of mRNA for 92-kD type IV collagenase and its inhibitor in aneurysmal, occlusive, and normal aorta. Arterioscler Thromb Vasc Biol 1995;15:1139-44.
12. Halpern VJ, Nackman GB, Gandhi RH, Irizarry E, Scholes JV, Ramey WG, et al. The elastase infusion model of experimental aortic aneurysms: synchrony of induction of endogenous proteinases with matrix destruction and inflammatory cell response. J Vasc Surg 1994;20:51-60.
13. McMillan WD, Tamarina NA, Cipollone M, Johnson DA, Parker MA, Pearce WH. Size matters: the relationship between MMP-9 expression and aortic diameter. Circulation 1997;96:2228-32.
14. Petersen E, Gineitis A, Wagberg F, Angquist KA. Activity of matrix metalloproteinase-2 and -9 in abdominal aortic aneurysms: relation to size and rupture. Eur J Vasc Endovasc Surg 2000;20:457-61.
15. Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC, Thompson RW. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg 1996;23:336-46.
16. Boyle JR, McDermott E, Crowther M, Wills AD, Bell PR, Thompson MM. Doxycycline inhibits elastin degradation and reduces metalloproteinase activity in a model of aneurysmal disease. J Vasc Surg 1998;27:354-61.
17. Pyo R, Lee JK, Shipley JM, Curci JA, Mao D, Ziporin SJ, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 2000;105:1641-9.
18. Longo GM, Mayhan WG, Prall AK, Fiotti N, Baxter BT. Aneurysm induction in mice deficient in metalloproteinase 9 or 12 [abstract]. Proceedings of the 55th Annual Meeting of the Society for Vascular Surgery; 2001 Jim 10-12; Baltimore, Md. p. 114. Manchester (MA): Society for Vascular Surgery.
19. McMillan WD, Pearce WH. Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. J Vasc Surg 1999;29:122-7.
20. Hovsepian DM, Ziporin SJ, Sakurai MK, Lee JK, Curci JA, Thompson RW. Elevated plasma levels of matrix metalloproteinase-9 (MMP-9) in patients with abdominal aortic aneurysms: a circulating marker of degenerative aneurysm disease. J Vasc Interv Radiol 2000;11:1345-52.
21. Lindholt JS, Vammen S, Fasting H, Henneberg EW, Heickendorff L. The plasma level of matrix metalloproteinase 9 may predict the natural history of small abdominal aortic aneurysms: a preliminary study. Eur J Vasc Endovasc Surg 2000;20:281-5.
22. Sangiorgi G, D'Averio R, Mauriello A, Bondio M, Pontillo M, Castelvecchio S, et al. Plasma levels of metalloproteinases-3 and -9 as markers of successful abdominal aortic aneurysm exclusion after endovascular graft treatment. Circulation 2001;104(Suppl):I288-95.
23. Golub LM, Lee HM, Lehrer G, Nemiroff A, McNamara TF, Kaplan R, et al. Minocycline reduces gingival collagenolytic activity during diabetes: preliminary observations and a proposed new mechanism of action. J Periodontal Res 1983;18:516-26.
24. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998;12:12-26.
25. Seftor EA, Seftor RE, Nieva DR, Hendrix MJ. Application of chemically modified tetracyclines (CMTs) in experimental models of cancer and arthritis. Adv Dent Res 1998;12:103-10.
26. Smith GN Jr, Yu LP Jr, Brandt KD, Capello WN. Oral administration of doxycycline reduces collagenase and gelatinase activities in extracts of human osteoarthritic cartilage. J Rheumatol 1998;25:532-5.
27. Smith GN Jr, Brandt KD, Hasty KA. Activation of recombinant human neutrophil procollagenase in the presence of doxycycline results in fragmentation of the enzyme and loss of enzyme activity. Arthritis Rheum 1996;39:235-44.
28. Curci JA, Petrinec D, Liao SX, Golub LM, Thompson RW. Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg 1998;28:1082-93.
29. Franklin IJ, Harley SL, Greenhalgh RM, Powell JT. Uptake of tetracycline by aortic aneurysm wall and its effect on inflammation and proteolysis. Br J Surg 1999;86:771-5.
30. Curci JA, Mao D, Bohner DG, Allen BT, Rubin BG, Reilly JM, et al. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg 2000;31:325-42.
31. Thompson RW, Baxter BT. MMP inhibition in abdominal aortic aneurysms: rationale for a prospective randomized clinical trial. Ann N Y Acad Sci 1999;878:159-78.
32. Mosorin M, Juvonen J, Biancari F, Satta J, Surcel HM, Leinonen M, et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg 2001;34:606-10.
33. Prall AK, Longo GM, Mayhan WG, Waltke EA, Fleckten B, Thompson RW, et al. Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J Vasc Surg. In press 2002.
34. Fujimoto N, Hosokawa N, Iwata K, Shinya T, Okada Y, Hayakawa T. A one-step sandwich enzyme immunoassay for inactive precursor and complexed forms of human matrix metalloproteinase 9 (92 kDa gelatinase/type IV collagenase, gelatinase B) using monoclonal antibodies. Clin Chim Acta 1994;231:79-88.
35. Hasan T, Kochevar IE, McAuliffe DJ, Cooperman BS, Abdulah D. Mechanism of tetracycline phototoxicity. J Invest Dermatol 1984;83: 179-83.
36. Cheek CC, Heymann HO. Dental and oral discolorations associated with minocycline and other tetracycline analogs. J Esthetic Dent 1999; 11:43-8.
37. Mellon M, Benbrook C, Lutz Benbrook K. Hogging it: estimates of antimicrobial abuse in livestock. Cambridge: Union of Concerned Scientists; 2001.
38. Sensakovic JW, Smith LG. oral antibiotic treatment of infectious diseases. Med Clin North Am 2001;85:115-23.
39. Speer BS, Shoemaker NB, Salyers AA. Bacterial resistance to tetracycline: mechanisms, transfer, and clinical significance. Clin Microbiol Rev 1992;5:387-99.
40. Makela M, Sorsa T, Uitto VJ, Salo T, Teronen O, Larjava H. The effects of chemically modified tetracyclines (CMTs) on human keratinocyte proliferation and migration. Adv Dent Res 1998;12: 131-5.
41. Bettany JT, Wolowacz RG. Tetracycline derivatives induce apoptosis selectively in cultured monocytes and macrophages but not in mesenchymal cells. Adv Dent Res 1998;12:136-43.
42. Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms. Circulation 1999;100:e20-8.
43. Petersen E, Boman J, Persson K, Arnerlov C, Wadell G, Juto P, et al. Chlamydia pneumoniae in human abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 1998;15:138-42.
44. Sinisalo J, Mattila K, Nieminen MS, Valtonen V, Syrjala M, Sundberg S, et al. The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk fictors and forearm basal nitric oxide production. J Antimicrob Chemother 1998; 41:85-92.
45. Thomas JG, Metheny RJ, Karakiozis JM, Wetzel JM, Grout RJ. Long-term sub-antimicrobial doxycycline (Periostat) as adjunctive managementin adult periodontitis: effects on subgingival bacterial population dynamics. Adv Dent Res 1998;12:32-9.
46. Brown PD. Ongoing trials with matrix metalloproteinase inhibitors. Expert Opinion Investig Drugs 2000;9:2167-77.